NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Background and purposeParkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.MethodsThis is an open-label, nonrandomized controlled trial. The subscales of the Cornell Medical Index, including somatization, anxiety, depression, maladjustment, sensitivity, anger, and tension, were used to evaluate neuropsychiatric symptoms. The study compared neuropsychiatric health status among 97 PD patients with neuropsychiatric symptoms, divided into two groups: BTX-A (n = 58) and citalopram hydrobromide (CH; n = 39). The BTX-A group received local injections targeting the bilateral glabella, orbicularis oculi muscle, forehead, bilateral lateral canthus, and temporal area. Patients in the CH group received daily doses ranging from 10 to 40 mg. The efficacy of BTX-A was assessed before and eight weeks after treatment, with outcomes compared to those of the CH group.ResultsThe BTX-A group showed significant reductions in somatization (p = 0.028), tension (p 0.05 for all parameters). Additionally, both groups showed comparable neuropsychiatric symptom improvement rates (64.3% vs. 73.7%, p > 0.05). These rates were calculated based on reductions in overall neuropsychiatric symptom severity scores.ConclusionsIn summary, BTX-A demonstrates efficacy in reducing multiple neuropsychiatric symptoms (such as tension, anxiety, depression, sensitivity, etc.) in PD, with comparable effectiveness to CH, supporting its consideration as an alternative therapeutic option.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.